China prazosin market is estimated to decline during the forecast period. China is among the emerging nations facing a burden of the continuous increase in high blood pressure. Lack of physical activity, obese population, alcohol consumption, and smoking are some of the major factors that lead to the increasing incidences of high blood pressure. The rising aging population may further increase the risk of hypertension in China. As per the United Nations (UN), in 2019, the percentage of the population aged 65 years and over in the country was 11.5%, which is expected to reach 16.9% by 2030. With the age, arteries get stiffer and thereby blood pressure goes up. Hypertension is one of the primary modifiable risk factors for CVD and its prevalence as well as severity both increase with age. However, the discontinuation of prazosin drugs due to various side effects further projected to decline the market growth during the forecast period.
Visit for Global Prazosin Market Report at: https://www.omrglobal.com/industry-reports/prazosin-market
China prazosin market is segmented on the basis of application into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for the significant share in the China prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, Prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.
The companies which are contributing to the growth of the China prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
Research Methodology
The market study of the China prazosin market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for prazosin market players, potential entrants, and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the market players, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints/Challenges
4.3. Opportunities
5. Market Segmentation
5.1. China Prazosin Market by Application
5.1.1. Cardiovascular Disease(CVD)
5.1.2. Neurological Syndromes
5.1.3. Prostate Disorders
5.1.4. Kidney Disorders
6. Company Profiles
6.1. Ajinomoto Co., Inc.
6.2. Johnlee Pharmaceuticals Pvt. Ltd.
6.3. Merck KGaA
6.4. Pfizer Inc.
6.5. R&D Systems Inc.
6.6. Renata Ltd.
6.7. Mylan N.V.
6.8. Standard Chem and Pharmaceuticals Co. Ltd.
6.9. Sun Pharmaceuticals Industries Ltd.
6.10. Teva Pharmaceuticals Industries Ltd.
1. CHINA PRAZOSIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. CHINA PRAZOSIN MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
2. CHINA PRAZOSIN MARKET SIZE, 2019-2026 ($ MILLION)